Novozymes Biopharma, part of Novozymes A/S, a leader in bioinnovation, is presenting two scientific posters on the manufacturing and use of recombinant albumin in formulation during PepTalk 2011, 10-14 January, San Diego, USA. The posters cover the company's latest research in the use of recombinant human albumin and its ability to address mmany of the formulation challenges faced by the industry. For more information, visit www.biopharma.novozymes.com
The first poster entitled "Recombinant human albumin: A multifunctional excipient for stable therapeutic protein formulations" demonstrates the unmatched ability of recombinant albumin to protect therapeutic proteins against chemical and physical degradation. The second, entitled "Optimizing Saccharomyces cerevisiae for the rapid development of animal-free biopharmaceutical manufacturing processes", provides insight into the benefits of the yeast strain in the production of recombinant proteins.
The two posters offer protein scientists new insight into formulation and manufacturing and highlight how recombinant albumin can help optimize current processes. The latest innovative solutions are described, which help to overcome some of the main challenges associated with the manufacture of protein therapeutics and biologics formulation development.
"Novozymes is delighted to present this information on the company's latest developments in recombinant albumin", said Dermot Pearson, marketing director at Novozymes Biopharma. "As one of the industry leaders, we believe that our studies significantly contribute to the development of the field and welcome the opportunity to share our advances with industry experts who can also benefit from the leading edge data."